Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!   Twitter
Follow us on Instagram!  Instagram 
Add us to your circle in Google+!

Google+ 

Subscribe to our channel on YouTube!  YouTube  


 

 

Bookmark and Share   Print  

New Funding Opportunities

The Cystic Fibrosis Foundation and Cystic Fibrosis Foundation Therapeutics announce these new funding opportunities for 2015.


Screening Improvement Program (SIP) for Optimizing the Diagnosis of Infants 

Early pre-symptomatic diagnosis through newborn screening (NBS) provides an opportunity to help control the disease through preventive medicine strategies and thereby enhance quality of life. After demonstration of benefits and endorsement — by both the Centers for Disease Control and Prevention and the Cystic Fibrosis Foundation (CFF) — the implementation of NBS for CF from 2006 to 2009 across the United States has provided many new opportunities for enhanced care, teaching, and research, but also occurred with such relative rapidity that a need for quality improvement and assurance has become apparent.

To this end, the CF Foundation has developed a Screening Improvement Program for Optimizing the Diagnosis of Infants. The Foundation invites quality improvement proposals from leaders of U.S. programs for projects designed to expedite the early diagnosis of CF through NBS.

The sponsoring institution should have a CF Foundation-accredited care center or affiliate program. The CF care center director or affiliate director must provide a letter affirming that the applicant will be integrated into the CF care center.

Each application should also engage the director of the regional NBS laboratory. All applicants must be either a U.S citizen or have a permanent resident visa. Proof of citizenship status is required at time of application.

Successful applicants will receive funding of up to $30,000 direct costs per year (plus 8% indirect costs) for one year and may be eligible for up two years. 

Please review the Policies and Guidelines for details and submission information.

back to top 


Modulating CFTR Gene Expression for Therapeutic Advantage 

The discovery of drugs that increase CFTR activity and/or residence in the plasma membrane to levels which result in clinical benefit is a milestone in drug development for human disease. This precedent suggests that such drugs may be even more effective if they have additional substrate on which to act. 

Cystic Fibrosis Foundation Therapeutics (CFFT) is soliciting proposals that will investigate the regulation of CFTR mRNA levels and methods to increase those levels. 

Additionally, this RFA seeks projects that will increase the translational efficiency and stability of CFTR mRNA as a potential mechanism for increasing CFTR protein expression. 
                                                                                                                                             
 CFFT is interested in proposals that will improve our understanding of:

  • The CFTR promoter
  • Splice modulation
  • Transcriptional activation
  • Other gene regulation mechanisms (i.e., microRNA, lncRNA, etc.)

Proposals will be accepted in three categories:

Please review the Policies and Guidelines for details and submission information.

back to top 


Delivery Technologies for CFTR Gene Replacement and Repair

Deadline: July 15, 2015, 5:00 pm (ET)

Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, is soliciting proposals that will develop nucleic acid delivery technologies to support CFTR gene editing and gene therapy. Emphasis will also be given to studies developing vectors and delivery mechanisms to be used with gene repair technologies in cell lines and animal models to support the development of CF therapeutics.

Research Objectives

The objective of this RFA is to fund highly meritorious research projects that will advance our understanding and development of nucleic acid delivery approaches in CF cell lines and animal models to support the development of CFTR gene repair and gene transfer technologies as a CF therapeutics strategy.

CFFT is accepting applications that focus on optimizing delivery agents for overcoming the barriers for delivery to CF cells.

Areas of interest include, but are not limited to:

  1. Novel nucleic acid delivery strategies into CF cells in vitro and in vivo for animal models 
  2. Optimizing the formulation of delivery tools including viral and non-viral vectors 
  3. Screening assays for optimizing and characterizing delivery systems 
  4. Studies for dosing and safety of delivery mechanisms for CF 
  5. Targeting to the airway and non-airway tissues (i.e. gut, pancreas) important in CF 
  6. Understanding and addressing the barriers for nucleic acid delivery into cells relevant to CF

Proposals will be accepted in three categories:

  • Research Grants: Funding of up to $150,000 per year for 2 years, plus eight percent (8%) indirect costs. A limited number of larger awards with strong justification (e.g., for animal models) will be considered for funding up to $250K per year, plus eight percent (8%) indirect costs. Open to international applicants, U.S. citizens and permanent residents.

  • Pilot and Feasibility Studies: Funding of up to $75,000 for one year, plus eight percent (8%) indirect costs. Open to international applicants, U.S. citizens and permanent residents.

  • Postdoctoral Fellowships: Funding of up to $46,250 for year 1 and $47,930 for year 2. No indirect costs permitted. Open to U.S. citizens and permanent residents only.

Applications will be accepted online at ProposalCENTRAL.

back to top 


Repairing CFTR Genetic Mutations for Research Tools and Therapeutics

Deadline: July 15, 2015, 5:00 pm, (ET)

Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, is soliciting proposals that will exploit gene repair technologies for developing research tools for therapeutic applications. Emphasis will be given to studies that focus on the repair of CFTR mutations that are uniquely amenable to gene editing strategies.

Research Objectives

The objective of this RFA is to fund highly meritorious research projects that will aide in the use of gene repair approaches to correct CFTR mutations. Projects of interest include using gene editing approaches for (1) the development of model systems to support CF basic research including cell lines and animal models and (2) to support the use of gene editing for therapeutics. Proposals that focus on utilizing gene editing strategies as a therapy to address CFTR mutations that are unresponsive to current CFTR modulator drugs are of high priority (e.g. nonsense, frameshift, splice site).

Areas of interest include, but are not limited to:

  1. Factors that control the efficiencies of homology directed repair verses non-homologous end-joining repair processes and methods to manipulate these processes in CF 
  2. Technological advancements of homing nucleases (CRISPR/Cas9, ZFNs, TALENs, meganucleases)
    for targeting and repairing CFTR mutations 
  3. Novel methods for delivering editing enzymes in vitro and/or in vivo 
  4. Biological endpoints and assays for CFTR gene repair 
  5. Tool development using gene editing for generating cell lines and animal models containing CFTR mutations in the native gene context 
  6. Understanding threshold and specificity of CFTR repair for a therapeutic index 
  7. Research supporting the development of CFTR gene repair as a therapeutic strategy

Proposals will be accepted in three categories:

  • Research Grants: Funding of up to $150,000 per year for 2 years, plus eight percent (8%) indirect costs.  A limited number of larger awards with strong justification (e.g., for animal models) will be considered for funding up to $250K per year, plus eight percent (8%) indirect costs. Open to international applicants, U.S. citizens and permanent residents.

  • Pilot and Feasibility Studies: Funding of up to $75,000 for one year, plus eight percent (8%) indirect costs. Open to international applicants, U.S. citizens and permanent residents.

  • Postdoctoral Fellowships: Funding of up to $46,250 for year 1 and $47,930 for year 2. No indirect costs permitted. Open to U.S. citizens and permanent residents only.

Applications will be accepted online at ProposalCENTRAL

back to top 

Updated: 5/15/2015

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.